Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective

Figure 4

Base-case probabilistic sensitivity analysis. Note: CE curves for risedronate, ibandronate, and teriparatide do not appear in the figure, as they are not considered cost-effective at any threshold in this analysis.